Increased glucocorticoid metabolism in diabetic kidney disease.
Daniel AckermannBruno VogtMurielle BochudMichel BurnierPierre-Yves MartinFred PaccaudGeorg EhretIdris GuessousBelen PonteMenno PruijmAntoinette Pechère-BertschiHeidi JaminRahel KlossnerBernhard DickMarkus G MohauptCarine Gennari-MoserPublished in: PloS one (2022)
In patients with diabetic kidney disease alternative MR activation is conceivable as cortisol and cortisone metabolites are increased. Systemic availability of active metabolites is counteracted via an increased HSD11B2 activity. As this cortisol deactivation is absent in HRMC and HRGEC, cortisol binding to the MR is enabled. Both, cortisol and aldosterone stimulation led to an increased expression of pro-fibrotic genes in HRMC. This mechanism was related to the MR as well as the GR and more marked in high glucose conditions linking the benefit of MRAs in diabetic kidney disease to these findings.